RVMD revenueQ3 2026$197.56M
RVMD revenue was $197.56M in fiscal Q3 2026 (ended Sep 30, 2026), compared with $0 a year earlier. For the full fiscal 2025 it was $0, compared with $0 in fiscal 2024.
Revolution Medicines Inc. (RVMD) financials
For fiscal 2025 (ended Dec 31, 2025), Revolution Medicines Inc. reported $0 of revenue and -$1.13B of net income.
- Revenue, FY2025
- $0
- Net income, FY2025
- -$1.13B
- Free cash flow, FY2025
- -$913.73M
- EPS, diluted, FY2025
- -$5.95
- Cash
- $615.91M
- Total debt
- $487.88M
- Market cap
- $41.59B
FY2018FY2025
FY2018FY2025
FY2018FY2025
RVMD revenue and earnings growth
RVMD net incomeQ3 2026-$407.46M
RVMD net income was -$407.46M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$305.21M a year earlier. For the full fiscal 2025 it was -$1.13B, compared with -$600.09M in fiscal 2024.
RVMD EPSQ3 2026-$1.90
RVMD diluted EPS was -$1.90 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$1.61 a year earlier. For the full fiscal 2025 it was -$5.95, compared with -$3.58 in fiscal 2024.
RVMD free cash flowQ3 2026-$419.35M
RVMD free cash flow was -$419.35M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$210.66M a year earlier. For the full fiscal 2025 it was -$913.73M, compared with -$567.74M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $11.58M | $35.38M | $29.39M | $42.98M | $50.04M | $20.16M |
| Research and development | $987.33M | $592.23M | $423.14M | $253.07M | $186.95M | $132.25M | $91.75M | $51.08M |
| Selling, general and admin | $195.04M | $97.30M | $75.62M | $40.59M | $30.45M | $21.43M | $12.41M | $9.41M |
| Operating income | -$1.18B | -$689.52M | -$487.19M | -$258.28M | -$188.01M | -$110.70M | -$54.12M | -$40.33M |
| Interest expense | $24.23M | $0 | $0 | $0 | $12.0K | $71.0K | $106.0K | $116.0K |
| Pre-tax income | -$1.13B | -$600.85M | -$439.89M | -$249.13M | -$187.09M | -$108.53M | -$52.04M | -$41.79M |
| Income tax | $0 | -$753.0K | -$3.52M | -$420.0K | $0 | -$371.0K | -$4.37M | - |
| Net income | -$1.13B | -$600.09M | -$436.37M | -$248.71M | -$187.09M | -$108.16M | -$47.66M | -$41.79M |
| EPS, basic | -$5.95 | -$3.58 | -$3.86 | -$3.08 | -$2.57 | -$2.01 | -$22.33 | -$21.24 |
| EPS, diluted | -$5.95 | -$3.58 | -$3.86 | -$3.08 | -$2.57 | -$2.01 | -$22.33 | -$21.24 |
| Diluted shares | 190.1M | 167.7M | 113.1M | 80.6M | 72.8M | 54.9M | 2.8M | 2.3M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $383.75M | $543.06M | $696.15M | $161.41M | $108.50M | $104.27M | $16.66M | $69.59M |
| Short-term investments | $1.64B | $1.75B | $1.16B | $483.53M | $468.56M | $336.47M | $106.10M | - |
| Receivables | $0 | - | - | - | - | - | - | - |
| Inventory | $0 | - | - | - | - | - | - | - |
| Current assets | $2.08B | $2.33B | $1.88B | $660.18M | $589.77M | $454.12M | $133.98M | - |
| Goodwill | $14.61M | $14.61M | $14.61M | $14.61M | $14.61M | $14.61M | $14.61M | - |
| Total assets | $2.35B | $2.56B | $2.06B | $811.93M | $737.99M | $567.40M | $220.53M | - |
| Current liabilities | $290.42M | $163.91M | $143.85M | $61.98M | $60.35M | $47.18M | $43.05M | - |
| Long-term debt | $0 | - | - | - | - | - | - | - |
| Total debt | $0 | - | - | - | - | - | - | - |
| Total liabilities | $723.21M | $293.10M | $235.51M | $126.74M | $135.42M | $92.72M | $67.99M | - |
| Shareholders' equity | $1.63B | $2.27B | $1.83B | $685.19M | $602.57M | $474.68M | -$152.57M | -$108.42M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$897.74M | -$557.44M | -$350.57M | -$224.40M | -$147.18M | -$100.06M | -$49.62M | $1.21M |
| Capital expenditures | $15.99M | $10.31M | $7.73M | $10.82M | $6.53M | $2.93M | $2.59M | $1.50M |
| Free cash flow | -$913.73M | -$567.74M | -$358.30M | -$235.22M | -$153.71M | -$103.00M | -$52.20M | -$286.0K |
| Investing cash flow | $118.06M | -$554.39M | -$342.60M | -$24.12M | -$142.12M | -$234.23M | -$101.97M | -$1.34M |
| Financing cash flow | $621.52M | $959.41M | $1.23B | $301.43M | $294.18M | $422.78M | $98.66M | $60.85M |
| Dividends paid | - | - | - | - | - | $0 | - | - |
| Stock-based compensation | $118.39M | $79.20M | $61.77M | $31.20M | $20.72M | $8.89M | $3.16M | $855.0K |
| Depreciation and amortization | $7.78M | $6.56M | $5.04M | $3.97M | $3.10M | $2.61M | $2.27M | $1.57M |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | -100.0% | -67.3% | 20.4% | -31.6% | -14.1% | 148.2% | - |
| Operating margin | - | - | -4207.1% | -730.0% | -639.7% | -257.5% | -108.2% | -200.0% |
| Net margin | - | - | -3768.3% | -703.0% | -636.6% | -251.6% | -95.2% | -207.2% |
| Free cash flow margin | - | - | -3094.1% | -664.8% | -523.0% | -239.6% | -104.3% | -1.4% |
| Return on equity | -69.3% | -26.5% | -23.9% | -36.3% | -31.0% | -22.8% | - | - |
| Return on assets | -48.0% | -23.5% | -21.2% | -30.6% | -25.4% | -19.1% | -21.6% | - |
| Current ratio | 7.14 | 14.20 | 13.06 | 10.65 | 9.77 | 9.63 | 3.11 | - |
| Debt to equity | 0.00 | - | - | - | - | - | - | - |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $197.56M | - | - | $0 | $0 | - | - | $0 | $0 | $0 | $0 | $742.0K |
| Cost of revenue | $327.0K | - | - | - | $0 | - | - | - | - | - | - | - |
| Gross profit | $197.23M | - | - | - | $0 | - | - | - | - | - | - | - |
| Research and development | $417.09M | $394.92M | $343.97M | $294.94M | $262.51M | $224.13M | $205.75M | $188.10M | $151.75M | $134.93M | $118.02M | $148.48M |
| Selling, general and admin | $153.29M | $110.21M | $101.25M | $66.68M | $52.76M | $40.58M | $35.01M | $28.21M | $23.96M | $21.71M | $22.84M | $32.24M |
| Operating income | -$373.15M | -$505.13M | -$445.22M | -$361.63M | -$315.27M | -$264.71M | -$240.76M | -$216.31M | -$175.71M | -$156.64M | -$140.86M | -$179.98M |
| Interest expense | $33.80M | $23.78M | $12.20M | $11.94M | $11.43M | $867.0K | $0 | $0 | $0 | - | - | - |
| Pre-tax income | -$409.81M | -$644.37M | -$453.82M | -$364.89M | -$305.21M | -$247.79M | -$213.42M | -$195.32M | -$156.29M | -$133.23M | -$116.00M | -$161.19M |
| Income tax | -$2.35M | - | - | $0 | $0 | - | - | -$753.0K | $0 | $0 | $0 | $343.0K |
| Net income | -$407.46M | -$644.37M | -$453.82M | -$364.89M | -$305.21M | -$247.79M | -$213.42M | -$194.57M | -$156.29M | -$133.23M | -$116.00M | -$161.54M |
| EPS, basic | -$1.90 | -$3.06 | -$2.29 | -$1.90 | -$1.61 | -$1.31 | -$1.13 | -$1.13 | -$0.94 | -$0.81 | -$0.70 | - |
| EPS, diluted | -$1.90 | -$3.06 | -$2.29 | -$1.90 | -$1.61 | -$1.31 | -$1.13 | -$1.13 | -$0.94 | -$0.81 | -$0.70 | - |
| Diluted shares | 214.9M | 210.9M | 198.1M | - | 189.2M | 188.6M | 188.1M | - | 166.8M | 165.1M | 164.7M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $615.91M | $815.43M | $440.94M | $383.75M | $217.44M | $402.44M | $333.55M | $543.06M | $201.26M | $275.71M | $288.43M | $696.15M |
| Short-term investments | $3.04B | $3.12B | $1.47B | $1.64B | $1.71B | $1.73B | $1.77B | $1.75B | $1.35B | $1.32B | $1.42B | $1.16B |
| Receivables | $230.72M | - | - | $0 | - | - | - | - | - | - | - | - |
| Inventory | $11.02M | - | - | $0 | - | - | - | - | - | - | - | - |
| Current assets | $3.98B | $4.03B | $1.97B | $2.08B | $1.98B | $2.18B | $2.13B | $2.33B | $1.58B | $1.62B | $1.73B | $1.88B |
| Goodwill | $14.61M | $14.61M | $14.61M | $14.61M | $14.61M | $14.61M | $14.61M | $14.61M | $14.61M | $14.61M | $14.61M | $14.61M |
| Total assets | $4.30B | $4.32B | $2.25B | $2.35B | $2.25B | $2.43B | $2.37B | $2.56B | $1.76B | $1.81B | $1.91B | $2.06B |
| Current liabilities | $475.67M | $354.06M | $289.60M | $290.42M | $245.62M | $184.53M | $158.60M | $163.91M | $110.86M | $105.33M | $93.72M | $143.85M |
| Long-term debt | $487.88M | $487.43M | - | $0 | - | - | - | - | - | - | - | - |
| Total debt | $487.88M | $487.43M | - | $0 | - | - | - | - | - | - | - | - |
| Total liabilities | $1.90B | $1.72B | $753.82M | $723.21M | $655.02M | $564.20M | $287.20M | $293.10M | $196.69M | $189.59M | $182.90M | $235.51M |
| Shareholders' equity | $2.40B | $2.61B | $1.50B | $1.63B | $1.60B | $1.87B | $2.08B | $2.27B | $1.57B | $1.62B | $1.73B | $1.83B |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$415.65M | -$387.32M | -$354.17M | -$274.24M | -$207.31M | -$221.76M | -$194.44M | -$138.29M | -$130.42M | -$128.17M | -$160.56M | -$120.56M |
| Capital expenditures | $3.70M | $2.29M | $1.54M | $1.93M | $3.35M | $7.45M | $3.27M | $1.22M | $3.52M | $2.40M | $3.17M | $2.32M |
| Free cash flow | -$419.35M | -$389.61M | -$355.70M | -$276.16M | -$210.66M | -$229.21M | -$197.70M | -$139.51M | -$133.94M | -$130.57M | -$163.73M | -$122.88M |
| Investing cash flow | $80.10M | -$1.66B | $172.62M | $74.88M | $24.85M | $34.28M | -$15.95M | -$392.90M | -$21.47M | $107.94M | -$247.97M | -$380.40M |
| Financing cash flow | $147.00M | $2.42B | $238.74M | $365.66M | -$1.59M | $256.58M | $874.0K | $873.80M | $77.29M | $7.50M | $810.0K | $839.35M |
| Stock-based compensation | $62.63M | $67.00M | $87.30M | $33.70M | $30.78M | $28.83M | $25.08M | $22.44M | $20.77M | $19.77M | $16.21M | $25.43M |
| Depreciation and amortization | $2.63M | $2.45M | $2.35M | $2.27M | $1.53M | $2.29M | $1.69M | $1.74M | $1.64M | $1.64M | $1.54M | - |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | - | - | - | -100.0% | - | -100.0% | -100.0% | -95.2% |
| Gross margin | 99.8% | - | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -188.9% | - | - | - | - | - | - | - | - | - | - | -24256.5% |
| Net margin | -206.2% | - | - | - | - | - | - | - | - | - | - | -21770.5% |
| Free cash flow margin | -212.3% | - | - | - | - | - | - | - | - | - | - | -16560.6% |
| Current ratio | 8.36 | 11.38 | 6.80 | 7.14 | 8.05 | 11.79 | 13.46 | 14.20 | 14.24 | 15.42 | 18.45 | 13.06 |
| Debt to equity | 0.20 | 0.19 | - | 0.00 | - | - | - | - | - | - | - | - |
Source: XBRL data Revolution Medicines Inc. files with the SEC, latest filing dated Nov 4, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
RVMD peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| RVMD | $0 | - | -$1.13B | - | $41.59B |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $249.05B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $207.00B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $101.48B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $57.55B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $36.71B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $16.98B |
| NBIX | $3.70B | +38.0% | $702.50M | 19.0% | $16.66B |
RVMD FAQ
7 questionsWhat is RVMD revenue?
Revolution Medicines Inc. (RVMD) reported $0 of revenue for fiscal 2025 (ended Dec 31, 2025).Is RVMD profitable?
No. Revolution Medicines Inc. reported a net loss of $1.13B for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does RVMD have?
Revolution Medicines Inc. reported $615.91M in cash and cash equivalents and $487.88M of debt on its most recent balance sheet in SEC filings.What is RVMD free cash flow?
Revolution Medicines Inc. generated -$913.73M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$897.74M less capital expenditures.What is RVMD earnings per share?
Diluted earnings per share were -$5.95 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did RVMD last report financial results?
The latest statements here come from Revolution Medicines Inc.'s 10-Q filed on Nov 4, 2026, covering the period ended Sep 30, 2026.Where does this RVMD financial data come from?
Quantisnow builds these statements from the structured XBRL data Revolution Medicines Inc. files with the SEC. It is provided for information only and is not investment advice.